Publications by authors named "W Blau"
Article Synopsis
- The European LeukemiaNet (ELN) updated its risk classification for acute myeloid leukemia (AML) patients in 2022 (ELN22) and a study evaluated its effectiveness on 1,570 newly diagnosed patients.
- Compared to the previous 2017 classification (ELN17), the new ELN22 showed a similar distribution of risk categories but reclassified 22% of patients, mostly into intermediate or adverse groups, resulting in better prognostic accuracy, particularly for overall survival (OS).
- The study found significant differences in survival rates based on specific gene mutations within the adverse risk group, highlighting the need for tailored treatment approaches based on genetic factors.
Article Synopsis
- In newly diagnosed acute myeloid leukemia (AML), immediate treatment is typical; however, sometimes treatment may be delayed to evaluate other health issues or risks.
- A study analyzed the effects of the timing of treatment initiation on outcomes for patients receiving venetoclax-based therapy, comparing two patient groups with average ages of 76 and 72.
- Results showed no significant difference in overall survival or complications (like severe infections) between those who started treatment within 10 days versus later, suggesting that delaying therapy may be safe for certain patients with proper monitoring.
Aims: To evaluate the efficacy and safety of nintedanib plus docetaxel in patients with advanced adenocarcinoma non-small cell lung cancer (NSCLC) who progressed after chemotherapy and immune checkpoint inhibitor (ICI) therapy.
Materials And Methods: VARGADO (NCT02392455) is an ongoing, prospective, non-interventional, real-world study of nintedanib plus docetaxel after first-line chemotherapy in the routine clinical treatment of patients with locally advanced, metastatic or locally recurrent adenocarcinoma NSCLC. Data were collected during routine visits.
Phage display technology (PD) is a powerful technique for the generation of tumor‑targeting antibodies. However, there are a number of different selection methods established in different laboratories around the world. Cell‑based PD panning methods using primary tumor cells are particularly heterogeneous between laboratories, which can lead to inconsistent results.
View Article and Find Full Text PDF